SaraMichellTolaneyMD

Oncology • Boston, MA

Breast Cancer, Hematologic Oncology

Instructor in Medicine, Dana-Farber Cancer Institute

Join to view full profile

Dr. Tolaney is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Tolaney's full profile

Already have an account?

Office
55 Fruit Street Yaw 7604
Massachusetts General Hospital
Boston, MA 02114
Phone+1 617-726-2782

Fax+1 617-394-3012

Education & Training

Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2005 - 2008
Johns Hopkins UniversityResidency, Internal Medicine, 2002 - 2005
University of California San Francisco School of MedicineClass of 2002

Certifications & Licensure

FL State Medical License 2022 - Present
MA State Medical License 2005 - 2026
American Board of Internal Medicine Medical Oncology

Clinical Trials

Bicalutamide in Treating Patients With Metastatic Breast Cancer Start of enrollment: 2007 Mar 23
Completed
Phase 2
Lapatinib Ditosylate and Akt Inhibitor MK2206 in Treating Women With Metastatic Breast Cancer Start of enrollment: 2011 Jan 01
Terminated
Phase 1
Cabozantinib in Women With Metastatic Hormone-Receptor-Positive Breast Cancer Start of enrollment: 2011 Oct 01
Active, not recruiting
Phase 2
Tivantinib in Treating Patients With Recurrent or Metastatic Breast Cancer Start of enrollment: 2012 Mar 01
Completed
Phase 2
A Safety, Pharmacokinetic and Pharmacodynamic Study of Kevetrin in Patients With Advanced Solid Tumors Start of enrollment: 2012 Oct 01
Completed
Phase 1
Cabozantinib for Metastatic Triple Negative BrCa Start of enrollment: 2013 Feb 01
Completed
Phase 2
T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial) Start of enrollment: 2013 May 01
Active, not recruiting
Phase 2
Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer.(MONALEESA-2) Start of enrollment: 2013 Dec 17
Completed
Phase 3
Study of LEE011 With Fulvestrant and BYL719 or BKM120 in Advanced Breast Cancer Start of enrollment: 2014 May 19
Completed
Phase 1
A Study of Abemaciclib (LY2835219) In Participants With Previously Treated Breast Cancer That Has Spread Start of enrollment: 2014 Jun 10
Completed
Phase 2
A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer Start of enrollment: 2014 Jul 22
Active, not recruiting
Phase 3
Cabozantinib +/- Trastuzumab In Breast Cancer Patients w/ Brain Metastases Start of enrollment: 2014 Nov 01
Completed
Phase 2
An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer. Start of enrollment: 2016 Mar 09
Completed
Phase 1, Phase 2
A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer Start of enrollment: 2016 Nov 14
Active, not recruiting
Phase 1
Adjuvant PVX-410 Vaccine and Durvalumab in Stage II/III Triple Negative Breast Cancer Start of enrollment: 2016 Aug 01
Active, not recruiting
Phase 1
Ribociclib (LEE011) Rollover Study for Continued Access Start of enrollment: 2016 Dec 15
Recruiting
Phase 2
A Study Of Changes In PD-L1 Expression During Preoperative Treatment With Nab-Paclitaxel And Pembrolizumab In Hormone Receptor-Positive Breast Cancer Start of enrollment: 2017 Feb 23
Active, not recruiting
Phase 1
CISPLATIN + AZD-1775 In Breast Cancer Start of enrollment: 2017 Jan 18
Completed
Phase 2
A Study Of Pembrolizumab In Combination With Trastuzumab-DM1 Start of enrollment: 2017 Feb 17
Active, not recruiting
Phase 1
A Randomized Phase II Study Of Eribulin Mesylate With or Without Pembrolizumab For Metastatic Hormone Receptor Positive Breast Cancer Start of enrollment: 2017 Mar 22
Completed
Phase 2
Phase II PEMBROLIZUMAB + PALLIATIVE RADIOTHERAPY IN BC Start of enrollment: 2017 May 22
Terminated
Phase 2
A Phase II Study of Nivolumab in Combination With Cabozantinib for Metastatic Triple-negative Breast Cancer Start of enrollment: 2017 Nov 30
Completed
Phase 2
Carboplatin +/- Nivolumab in Metastatic Triple Negative Breast Cancer Start of enrollment: 2018 Jan 30
Active, not recruiting
Phase 2
Olaparib + Sapacitabine in BRCA Mutant Breast Cancer Start of enrollment: 2018 Oct 01
Active, not recruiting
Phase 1
NIMBUS: Nivolumab Plus Ipilimumab in Metastatic Hypermutated HER2-negative Breast Cancer Start of enrollment: 2019 Mar 08
Active, not recruiting
Phase 2
Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC Start of enrollment: 2020 Sep 23
Active, not recruiting
Phase 2
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC Start of enrollment: 2020 Jul 20
Recruiting
Phase 2
ATEMPT 2.0: Adjuvant T-DM1 vs TH Start of enrollment: 2021 Jun 16
Recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

Incidence, treatment patterns, and mortality for patients with breast cancer during the first year of the COVID-19 pandemic: a population-based study.
José Pablo Leone, Julieta Leone, Michael J Hassett, Rachel A Freedman, Jorge Avila
Breast Cancer Research and Treatment. 2024-12-02
Globalization of clinical research in oncology: Status, challenges, and future directions.
Ana Tečić Vuger, Robert Separovic, Sara M Tolaney, Dario Trapani
Journal of Cancer Policy. 2024-12-01
Immune checkpoint inhibitors for patients with metastatic triple-negative inflammatory breast cancer (INCORPORATE): An international cohort study.
Carmine Valenza, Dario Trapani, Paola Zagami, Gabriele Antonarelli, Luca Boscolo Bielo
European Journal of Cancer. 2024-12-01

Journal Articles

Effect of Eribulin with or Without Pembrolizumab on Progression-Free Survival for Patients with Hormone Receptor–Positive, ERBB2-Negative Metastatic Breast Cancer
Sara M Tolaney, Gerburg Wulf, Laura Spring, Beth Overmoyer, Ann H Partridge, Eric P Winer, Ian E Krop, JAMA Oncology

Lectures

Randomized phase II study of eribulin mesylate (E) with or without pembrolizumab (P) for hormone receptor-positive (HR+) metastatic breast cancer (MBC).
2019 ASCO Annual Meeting - 6/1/2019
New Frontiers in HER2-Positive Breast Cancer
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
Updated efficacy, safety, & PD-L1 status of patients with HR+, HER2- metastatic breast cancer administered abemaciclib plus pembrolizumab.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
Impact of abemaciclib on the time to subsequent chemotherapy and the time to second disease progression across the MONARCH 2 and 3 studies.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
Join now to see all

Press Mentions

Trial Data Helped Guide Treatment of Stage II-III Triple-Negative Breast CancerDecember 11th, 2024
When or Whether to Give Immunotherapy in Early Breast CancerNovember 19th, 2024
INAVO120 Trial Tests Inavolisib in HR+, HER2-, PIK3C-Alpha-Mutated DiseaseOctober 30th, 2024
Join now to see all